Cobitolimod 500 mg ( DrugBank: Cobitolimod )


1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis1

97. Ulcerative colitis


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04985968
(ClinicalTrials.gov)
November 24, 202122/7/2021The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative ColitisA Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative ColitisUlcerative ColitisDrug: Cobitolimod 250 mg;Drug: Cobitolimod 500 mg;Drug: PlaceboInDex PharmaceuticalsNULLRecruiting18 YearsN/AAll440Phase 3Hungary